Why the study?
The study was conducted to examine patients' experiences of vagal nerve stimulation (VNS), with a special interest in patients with cognitive deficit.
Does vagal nerve stimulation provide different benefits in pharmacoresistant epilepsy patients with versus without cognitive deficits?
Does vagal nerve stimulation provide different benefits in pharmacoresistant epilepsy patients with versus without cognitive deficits?
VNS treatment in pharmacoresistant epilepsy yields higher seizure reduction in patients without cognitive deficits, while those with cognitive deficits experience other subjective benefits.
May inform VNS counseling by cognitive status in epilepsy; leaves open whether status modifies response in prospective trials.
INTRODUCTION: The purpose of this study was to examine patients' experiences of vagal nerve stimulation (VNS) with a special interest in patients with cognitive deficit (CD). MATERIALS AND METHODS: An open, retrospective study was conducted on 82 patients with pharmacoresistant epilepsy, who were treated with VNS for at least 10 months. Based on the inability to live independently, they were divided into two groups: patients with cognitive deficit (CD group) and patients without cognitive deficit (non-CD group). A specially designed questionnaire was used for semi-structured interviews about patients' experiences of VNS treatment. RESULTS: Approximately one-third described a continuous reduction of seizure frequency of 50% or more and were regarded as responders. Fewer subjects in the CD group were responders than in the non-CD group. Approximately one-third of all subjects had no positive effect of VNS treatment. More CD patients described additional improvements and the most common were milder seizures and improved alertness. The most commonly reported adverse effect was hoarseness. DISCUSSION: VNS treatment in patients without CD had better effect on seizure frequency reduction than in patients with CD, but many patients with CD reported other benefits from the treatment. CONCLUSION: Non-CD patients had higher seizure frequency reduction than CD patients during VNS treatment, but many CD patients described other benefits.
No takes yet. Share an insight, caveat, or question.
Pipan et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: